Read More Pharma Industry News AbbVie to develop amylin analog for obesity treatment in $350m licensing deal with Gubra AbbVie has taken a significant step into obesity treatment through a licensing agreement with Denmark-based Gubra, a company… byPallavi MadhirajuMarch 3, 2025